MENS Jyong Biotech (MENS) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001954488

Quote by TradingView

SEC filings

Insider buyers, 180 days

House members buying, 1 year

STOCK Act, US House only, disclosed up to 45 days after the trade

Funds added, last quarter

13F, latest reported quarter

MENS filings, in plain words

Read the full summary

The latest 5% ownership filing is a 13D by Perfect Minds Co., Ltd, filed 2026-04-24, for 33.3% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Jyong Biotech insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Jyong Biotech Ltd. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Foreign private issuer: its insiders are exempt from SEC Form 4 and report in the home market, so their buys and sells do not appear here.

Insider

Filed

Value

Since filing

no insider purchases or sales on record

0 transactions on record

See all insider buying · insider selling

Seven facts, ranked against the sector · Rank is not a forecast

Insiders

no insider buys or sells on file

Congress

no House purchase disclosed in the last 12 months

Funds

10 funds bought in last quarter

below 82% of Pharma & Biotech

Revenue

no revenue reported in any filing

Margin

no margin: no revenue reported

Buybacks

no share repurchases reported

Short interest

0.8% of the float short (float per yahoo 2026-10-27) · 5.3 days to cover · settled 2026-10-15

below 83% of Pharma & Biotech

What changed in the last 30 days

Nothing new filed in the last 30 days

Watch MENS

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

Who owns MENS: institutional holders (13F)

13F holdings, latest reported quarter

BlackRock, Inc.

260,317 sh

$538.9K

GEODE CAPITAL MANAGEMENT, LLC

68,882 sh

$142.6K

XTX Topco Ltd

29,066 sh

$60.2K

RENAISSANCE TECHNOLOGIES LLC

22,900 sh

$47.4K

China Universal Asset Management Co., Ltd.

12,100 sh

$25.0K

Congress trades in MENS

No Congress trades reported

No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

13D: intends to influence · 13G: passive

Perfect Minds Co., Ltd

Activist 13D · 2026-04-24

33.34%

Innovation Global Group Limited

Activist 13D · 2026-04-24

33.34%

Unity Trust Limited as trustee of The Innovation Trust

Activist 13D · 2026-04-24

33.34%

Ms. Kuo Fu-Feng

Activist 13D · 2026-04-24

33.34%

MENS planned insider sales (Form 144)

No planned-sale notices

No insider has filed to sell. Watch this after a run-up.

MENS mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).

Invesco Nasdaq Biotechnology ETF

$8.6K position · as of 2026-05-31

0.0%

SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio

Live price

Daily candles from TradingView, under their licence. No filings marked.

Show the live price chart

Why this name is on the desk

The complete filing record, in one place.

The record shows 10 funds added last quarter. Each figure is a federal filing, dated the day it went public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector by SEC SIC code

UTHR CPIX MRNA REGN LLY ALNY MDGL CITR DNA VRTX NUVL TWST

MENS financials

Fundamentals

Annual figures from XBRL filings. Pick a past date to see them as known then.

	2025-12	2024-12	2023-12	2022-11
Operating income	-$2.6M	-$2.1M	-$2.8M	n/a
Net income	-$4.7M	-$3.0M	-$4.4M	n/a
EPS (diluted)	-0.06	-0.04	-0.06	n/a
Operating cash flow	-$3.0M	-$3.6M	-$2.6M	n/a
Long-term debt	$2.1M	n/a	n/a	n/a
Buybacks	n/a	n/a	n/a	$112.5M

SEC XBRL, fiscal years, as known on 2026-10-28

MENS Stock Sonar score 2/7 axes

Find similar shapes Compare

Institutional and government

Inputs

Funds adding, latest quarter10 · 18 pct, sector of 698
Congress net buyers, 365dno Congress trades in 365 days
Federal contracts, 180dno federal contracts in 180 days
Lobbying spend, 4 quartersno lobbying filings in the last four quarters

Risk and compliance

Inputs

Short interest, % of float+0.8% · 82 pct, sector of 816
Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)

5 not measured: Profitability, Financial health, Growth, Insider conviction, US patents

Profitability needs 2 of 4 inputs, 0 present: fewer than four consecutive quarters of net income; fewer than four consecutive quarters of operating income
Financial health needs 1 of 2 inputs, 0 present: equity is zero or negative, the ratio has no meaning; needs four quarters of operating cash flow
Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

2 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing

Insider buying Insider selling Congress stock trades Activist 13D stakes Form 144 planned sales CEO pay vs performance All companies